Sugi Predict

Sugi Predict / Compounds / SCHEMBL475538

SCHEMBL475538

SCHEMBL475538

CC(C)(C)N1CCCC(NC(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.42
▸ CA2 P00918 4/20 0.42
▸ CA12 O43570 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ SIGMAR1 Q99720 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ USP30 Q70CQ3 1/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ GAA P10253 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ EPHX1 P07099 2/20 0.35
▸ CACNA1H O95180 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CTSK P43235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612827 1.00 CA1 (0.42) CA1CA2CA12CA9SIGMAR1
SCHEMBL1061969 1.00 CA1 (0.42) CA1CA2CA12CA9SIGMAR1
SCHEMBL1564567 0.95 SIGMAR1 (0.41) CA1CA2CA12CA9SIGMAR1
SCHEMBL28509408 0.95 SIGMAR1 (0.41) CA1CA2CA12CA9SIGMAR1
SCHEMBL1265815 0.89 CTSK (0.39) CA1CA2CA12CA9SIGMAR1
SCHEMBL743576 0.89 CTSK (0.39) CA1CA2CA12CA9SIGMAR1
SCHEMBL1487188 0.89 CTSK (0.39) CA1CA2CA12CA9SIGMAR1
SCHEMBL12791555 0.86 CA1 (0.53) CA1CA2CA12CA9SIGMAR1
SCHEMBL8227340 0.86 CA1 (0.53) CA1CA2CA12CA9SIGMAR1
SCHEMBL8222138 0.82 BTK (0.40) CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 — — US claimed
US-12325696-B2 Indazole derivative, preparation method therefor, and pharmaceutical application thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2025-06-10 — — US disclosed
US-20250002470-A1 NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ZHEJIANG AIXPLORER BIOTECH CO., LTD. (CN) 2025-01-02 — — US disclosed
EP-4421068-A1 NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Zhejiang Aixplorer Biotech Co., Ltd. (CN) 2024-08-28 — — EP disclosed
CN-115246817-B Crystal form beta of compound A benzoate, preparation method thereof and pharmaceutical composition containing crystal form beta 深圳信立泰药业股份有限公司 2024-06-18 — — CN disclosed
CN-113493435-B Amorphous compound A benzoate, preparation method thereof and pharmaceutical composition containing amorphous compound A benzoate 深圳信立泰药业股份有限公司 2024-01-26 — — CN disclosed
CN-117126151-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 — — CN disclosed
CN-117126152-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 — — CN disclosed
CN-117069712-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 — — CN disclosed
CN-117069713-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 — — CN disclosed
EP-2524917-A1 FUSED PYRIDINE DERIVATIVES Xuanzhu Pharmaco., Ltd. (CN) 2012-11-21 — — EP disclosed
US-20120289497-A1 FUSED PYRIDINE DERIVATIVES Xuanzhu Pharma Co., Ltd. (CN) 2012-11-15 — — US disclosed
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 — — US disclosed
US-20120029000-A1 PROCESS FOR THE PREPARATION OF ALOGLIPTIN MAPI PHARMA LIMITED (IL) 2012-02-02 — — US disclosed
EP-2410855-A1 PROCESS FOR THE PREPARATION OF ALOGLIPTIN Mapi Pharma Limited (IL) 2012-02-01 — — EP disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 — — US disclosed
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-01-27 — — US disclosed
EP-2269986-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR Sumitomo Chemical Company, Limited (JP) 2011-01-05 — — EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 — — US disclosed
CN-1476442-A Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity — 2004-02-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289497-A1 FUSED PYRIDINE DERIVATIVES GPR119, INSR, IAPP CA1 4674/4885CA2 3939/4885CA12 4864/4885
US-20120029000-A1 PROCESS FOR THE PREPARATION OF ALOGLIPTIN DPP7, DPP4, DPP8 CA1 2496/4885CA2 1963/4885CA12 2507/4885
US-20250002470-A1 NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF NOD1, NLRP3, NLRP1 CA1 3761/4885CA2 2224/4885CA12 4439/4885
US-12325696-B2 Indazole derivative, preparation method therefor, and pharmaceutical application thereof CYP19A1, HSD17B11, CYP51A1 CA1 4362/4885CA2 4308/4885CA12 3861/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CA1 1413/4885CA2 222/4885CA12 3287/4885
US-20110021780-A1 MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR PDCD2L, NOTUM, OXA1L CA1 3008/4885CA2 2967/4885CA12 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.